Myriad Genetics (MYGN) Receives a Sell from Barclays

By Ryan Adsit

In a report released yesterday, Jack Meehan from Barclays maintained a Sell rating on Myriad Genetics (MYGNResearch Report), with a price target of $22. The company’s shares closed last Monday at $22.97, close to its 52-week low of $22.07.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 5.5% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, IQVIA Holdings Inc, and Genomic Health.

Currently, the analyst consensus on Myriad Genetics is a Moderate Sell with an average price target of $33.83, representing a 47.0% upside. In a report issued on August 14, J.P. Morgan also maintained a Sell rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

Myriad Genetics’ market cap is currently $1.7B and has a P/E ratio of 388.70. The company has a Price to Book ratio of 1.56.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life.